Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9827602 | 0.91 | CYP1A2 (0.47) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10533992 | 0.89 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL5690187 | 0.85 | CYP1A2 (0.57) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL29399169 | 0.85 | CYP1A2 (0.57) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL117318 | 0.85 | CYP1A2 (0.57) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| Hydrochloric Acid SCHEMBL28287683 | 0.83 | CYP1A2 (0.56) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL8617798 | 0.81 | CYP1A2 (0.58) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL7247476 | 0.81 | CYP1A2 (0.54) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL14478292 | 0.81 | CYP1A2 (0.54) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL14478261 | 0.81 | CYP1A2 (0.54) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| CN-101070316-A | Diaryl acid derivatives as PPAR receptor ligands | AVENTIS PHARMA GMBH (DE) | 2007-11-14 | — | — | CN | disclosed |
| CN-1331862-C | Diaryl acid derivatives as PPAR receptor ligands | AVENTIS PHARAMCEUTICALS PRODUC (DE) | 2007-08-15 | — | — | CN | disclosed |
| EP-0784052-B1 | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation | AVENTIS HOLDINGS INC (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6635655-B1 | Agonists or antagonists of peroxisome proliferator-activated receptors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-21 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1177187-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| EP-0397697-A4 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | — | 1991-07-03 | — | — | EP | disclosed |
| US-5028615-A | Treatment of hypersensitivity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-07-02 | — | — | US | disclosed |
| EP-0397697-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4?. | RORER INT OVERSEAS (US) | 1990-11-22 | — | — | EP | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920133-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920131-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004304-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0260305-A4 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-04 | — | — | EP | disclosed |
| EP-0260305-A1 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS. | RORER INT OVERSEAS (US) | 1988-03-23 | — | — | EP | disclosed |
| WO-1987005510-A1 | QUINOLINYL ETHER OR THIOETHER TETRAZOLES AS AGENTS FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-09-24 | — | — | WO | disclosed |